Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Acquired by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. boosted its position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 38.4% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,611 shares of the company’s stock after purchasing an additional 1,002 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Day One Biopharmaceuticals were worth $51,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of DAWN. Essex Investment Management Co. LLC bought a new stake in shares of Day One Biopharmaceuticals during the 3rd quarter worth about $2,566,000. Handelsbanken Fonder AB grew its position in Day One Biopharmaceuticals by 16.9% during the third quarter. Handelsbanken Fonder AB now owns 27,000 shares of the company’s stock valued at $376,000 after purchasing an additional 3,900 shares in the last quarter. Point72 DIFC Ltd purchased a new position in Day One Biopharmaceuticals during the second quarter valued at approximately $124,000. Point72 Asset Management L.P. purchased a new position in Day One Biopharmaceuticals during the second quarter valued at approximately $6,480,000. Finally, Deerfield Management Company L.P. Series C lifted its stake in Day One Biopharmaceuticals by 65.6% in the second quarter. Deerfield Management Company L.P. Series C now owns 2,923,137 shares of the company’s stock valued at $40,281,000 after acquiring an additional 1,157,825 shares during the last quarter. 87.95% of the stock is currently owned by institutional investors.

Insider Transactions at Day One Biopharmaceuticals

In related news, CFO Charles N. York II sold 2,633 shares of the business’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $14.00, for a total value of $36,862.00. Following the transaction, the chief financial officer now owns 232,485 shares in the company, valued at $3,254,790. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 30,000 shares of Day One Biopharmaceuticals stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $14.22, for a total value of $426,600.00. Following the completion of the sale, the insider now directly owns 1,097,535 shares of the company’s stock, valued at approximately $15,606,947.70. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Charles N. York II sold 2,633 shares of Day One Biopharmaceuticals stock in a transaction on Friday, August 16th. The shares were sold at an average price of $14.00, for a total transaction of $36,862.00. Following the completion of the sale, the chief financial officer now directly owns 232,485 shares of the company’s stock, valued at approximately $3,254,790. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 49,248 shares of company stock worth $697,082. Company insiders own 8.40% of the company’s stock.

Day One Biopharmaceuticals Trading Up 2.3 %

Shares of DAWN opened at $15.15 on Wednesday. The firm’s 50 day moving average is $14.20 and its 200-day moving average is $14.38. The stock has a market capitalization of $1.53 billion, a PE ratio of -14.71 and a beta of -1.51. Day One Biopharmaceuticals, Inc. has a 12 month low of $10.90 and a 12 month high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $0.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.58. The firm had revenue of $93.76 million during the quarter, compared to the consensus estimate of $15.05 million. During the same period last year, the business earned ($0.54) earnings per share. Equities research analysts predict that Day One Biopharmaceuticals, Inc. will post -1.22 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on DAWN shares. Wedbush restated an “outperform” rating and issued a $33.00 price objective on shares of Day One Biopharmaceuticals in a research note on Thursday, July 25th. JPMorgan Chase & Co. lowered their target price on shares of Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Bank of America raised shares of Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and increased their price objective for the stock from $11.00 to $24.00 in a report on Thursday, August 1st. Needham & Company LLC reissued a “buy” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. Finally, TD Cowen upgraded shares of Day One Biopharmaceuticals to a “strong-buy” rating in a research report on Monday. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $35.71.

Day One Biopharmaceuticals Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.